As pharma companies around the world race to develop a viable treatment for Covid-19, a number of therapeutic candidates have emerged as potential solutions. One of the most promising drugs currently being trialled is remdesivir, an antiviral medication originally developed by Gilead Sciences to treat Ebola. We take a look at the current state of remdesivir and other Covid-19 candidates to find out more about the race to find a cure.

Also in this issue, we investigate the ongoing backlash against Aspirin and ibuprofen, find out if a sophisticated laboratory model of the human body could help practitioners to detect harmful or adverse effects of drugs before they are prescribed to patients, and delve into the complex subject of drug pricing to see if crisis situations should change the way that regulators approach the issue.

Plus, we take a look at the next wave of anticoagulants, examine ViiV Healthcare and UNC-Chapel Hill’s “induce and reduce” approach to eliminating HIV, investigate what the Veeva vs IQVIA anti-competitive lawsuit means for pharma data issues and ownership, and find out if nanoparticles are the solution to unlocking the pharma benefits of turmeric.